Adaptimmune Limited Company Profile
Adaptimmune Limited is focused on the use of T cell therapy to treat HIV and cancer. It aims to utilize the body’s own machinery – the T lymphocyte cell – to target and destroy cancerous or infected cells. Established in July 2008, Adaptimmune was set up to develop Immunocore Ltd’s (formerly Avidex/MediGeneLtd’s) unique T cell receptor engineering technology for adoptive T cell therapy. Specifically, Adaptimmune makes use of the body’s ability to recognize infected or cancerous cells by enhancing the power of the T cell receptor (TCR) on killer T cells. Cancerous or virally infected cells will typically present small parts or peptides of larger viral proteins or abnormal cancer proteins on their surface, offering a "molecular fingerprint", called an epitope, for killer T-cells from the immune system to identify. In a healthy individual, this triggers an immune response, eliminating the affected cell. However, viruses such as HIV mutate rapidly, swiftly disguising their fingerprints to allow them to hide from killer T-cells while cancer proteins are usually derived from self-proteins against which natural TCRs do not respond. Adaptimmune’s technology uniquely enhances the natural TCR affinity to either viral or cancer protein epitopes on an individual patient’s cells overcoming these obstacles for therapeutic benefit.
Adaptimmune has undertaken significant preclinical development with a number of pipeline TCRs to demonstrate their potency and specificity in vitro. The TCR in the current sarcoma study is specific to the cancer testis antigen targets NY-ESO-1 157-165 (HLA A2; SLLMWITQC). This TCR and another TCR specific for MAGE A3168-176 (HLA A1; EVDPIGHLY) were engineered using Adaptimmune’s proprietary TCR engineering platform and are already under evaluation in other clinical trials in multiple myeloma and metastatic melanoma, with other cancers in planning. Adaptimmune has a pipeline of similar TCRs in preclinical development in both cancer and HIV.
57c Milton Park
Phone: +44 (0) 1235 438642
Fax: +44 (0) 1235 438607
16 January 2013: Allendale, USA, & Oxford, UK, – NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy LLC, together with Adaptimmune Limited and Adaptimmune LLC ...
Abstracts Published in Today’s Issue of the Journal Blood (Oxford, UK and Philadelphia, PA) 16 November, 2012. Adaptimmune announces the publication of dual abstracts in today’s issue of...
PCT enters Into a Cell Therapy Manufacturing Services Agreement with Adaptimmune NBS’ Progenitor Cell Therapy (PCT) to provide Cell Product Development and Manufacturing for Adaptimmune...
16 November, 2012: Oxford, UK and Philadelphia, USA - Adaptimmune announces the publication of dual abstracts in today's issue of the Journal Blood, which report preliminary results from ...
10 December 2012: Atlanta, USA and Oxford, UK - Adaptimmune today announces the release of preliminary results from an early phase clinical study using patients' own T cells that have been ...
Study reports encouraging response rates, and data support safety and preliminary proof of mechanism (Atlanta, GA and Oxford, UK) 10 December, 2012. Adaptimmune today announces the release of prelimi...
(Oxford, UK and Philadelphia, PA) 7 March 2011. Adaptimmune Limited today announced that it has launched a US subsidiary, Adaptimmune LLC, located in Philadelphia, and appointed Dr Gwen Binder-Sc...
Drugs and Medications
Adaptimmune Limited is focused on the use of T cell therapy to treat HIV and cancer. It aims to utilize the body’s own machinery – the T lymphocyte cell – to target and destroy can...
Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located...
More Information about "Adaptimmune Limited" on BioPortfolio
We have published hundreds of Adaptimmune Limited news stories on BioPortfolio along with dozens of Adaptimmune Limited Clinical Trials and PubMed Articles about Adaptimmune Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Adaptimmune Limited Companies in our database. You can also find out about relevant Adaptimmune Limited Drugs and Medications on this site too.